CNS PharmaceuticalsCNSP
13F holders, Q1 2026 (March 31)11holders +2
4new positions
2sold out
$2.39avg. 13F price*
At the end of Q1 2026, 11 institutions reported holding CNS Pharmaceuticals Inc. (CNSP) in their 13F filings, up 2 from Q4 2025. 4 opened new positions and 2 sold out. The largest holders were Stonepine Capital Management, LLC ($146K), Ikarian Capital, LLC ($110K) and Geode Capital Management, LLC ($56K).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H508
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $59K |
| Exits | 2 | $81K |
All 13F filers, Q4 2025 → Q1 2026: 36,792 shares bought and 15,433 shares sold, net +21,359 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Stonepine Capital Management, LLC | 0.13% | Add +24.9% | 61,000 | $146K |
| Ikarian Capital, LLC | 0.02% | No change | 45,830 | $110K |
| Geode Capital Management, LLC | 0.00% | New | 23,189 | $56K |
| Boothbay Fund Management, LLC | 0.00% | No change | 13,524 | $32K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,310 | $3K |
| UBS Group AG | 0.00% | Add +19.3% | 729 | $2K |
| Barrett & Company, Inc. | 0.00% | No change | 8 | $19 |
| MAI Capital Management | 0.00% | No change | 3 | $8 |
| Danske Bank A/S | 0.00% | No change | 1 | $2 |
| Citigroup Inc. | 0.00% | New | 1 | $2 |
| Caitong International Asset Management Co., Ltd | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is CNSP's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.